These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16873566)

  • 1. Interferon alpha sensitisation induced fatal renal insufficiency in a patient with chronic myeloid leukaemia: case report and review of literature.
    Colovic M; Jurisic V; Jankovic G; Jovanovic D; Nikolic LJ; Dimitrijevic J
    J Clin Pathol; 2006 Aug; 59(8):879-81. PubMed ID: 16873566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-alpha-induced focal segmental glomerulosclerosis in chronic myelogenous leukemia: a case report and review of the literature.
    Bremer CT; Lastrapes A; Alper AB; Mudad R
    Am J Clin Oncol; 2003 Jun; 26(3):262-4. PubMed ID: 12796597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombotic microangiopathy associated with alpha-interferon therapy for chronic myeloid leukaemia.
    Galesic K; Bozic B; Racic I; Scukanec-Spoljar M
    Nephrology (Carlton); 2006 Feb; 11(1):49-52. PubMed ID: 16509932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Occurrence of autoimmune complications in patients with chronic myelocytic leukemia during treatment with interferon alfa].
    Tóthová E; Stecová N; Kafková A; Fricová M; Svorcová E
    Vnitr Lek; 2002 May; 48(5):380-3. PubMed ID: 12061203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Alpha interferon in children with Philadelphia chromosome-positive chronic myeloid-leukaemia].
    Ben Lakhal R; Aissaoui L; Jeddi R; Ayari B; Ben Abid H; Belhadj Ali Z; Gouider E; Meddeb B; Hafsia R; Hafsia A
    Tunis Med; 2005 May; 83(5):296-9. PubMed ID: 16044905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia.
    Carella AM; Chimirri F; Podestà M; Pitto A; Piaggio G; Dejana A; Lerma E; Pollicardo N; Vassallo F; Soracco M; Benvenuto F; Valbonesi M; Carlier P; Vimercati R; Prencipe E; Gatti AM; Ferrara RA; Incagliato M; Florio G; Frassoni F
    Bone Marrow Transplant; 1996 Feb; 17(2):201-5. PubMed ID: 8640167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial expression of interferon alpha receptor 2 (IFNAR2) on CD34-positive cells and its down-regulation correlate with clinical response to interferon therapy in chronic myelogenous leukemia.
    Ito K; Tanaka H; Ito T; Sultana TA; Kyo T; Imanaka F; Ohmoto Y; Kimura A
    Eur J Haematol; 2004 Sep; 73(3):191-205. PubMed ID: 15287917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection.
    Thia TJ; Tan HH; Chuah TH; Chow WC; Lui HF
    Singapore Med J; 2008 Mar; 49(3):e86-9. PubMed ID: 18362995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrotic syndrome associated with alpha interferon therapy in chronic myeloid leukemia.
    Budak-Alpdoğan T; Lawrence RA; Bayik M; Akoğlu E
    Clin Nephrol; 1997 Jul; 48(1):59-60. PubMed ID: 9247783
    [No Abstract]   [Full Text] [Related]  

  • 10. Membranoproliferative glomerulonephritis secondary to chronic myeloid leukemia.
    Subramanian M; Kilara N; Manjunath R; Mysorekar V
    Saudi J Kidney Dis Transpl; 2010 Jul; 21(4):738-41. PubMed ID: 20587884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapidly progressive renal graft failure associated with interferon-alpha treatment in a patient with chronic myelogenous leukemia.
    Bren A; Kandus A; Ferluga D
    Clin Nephrol; 1998 Oct; 50(4):266-7. PubMed ID: 9799075
    [No Abstract]   [Full Text] [Related]  

  • 12. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
    N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.
    Tóthová E; Kafková A; Fricová M; Benová B; Kirschnerová G; Tóthová A
    Neoplasma; 2005; 52(1):63-7. PubMed ID: 15739029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-alfa for chronic myeloid leukemia.
    Baccarani M; Russo D; Rosti G; Martinelli G
    Semin Hematol; 2003 Jan; 40(1):22-33. PubMed ID: 12563609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous complete hematological and cytogenetic remission with molecular minimal residual disease 9 years after discontinuation of interferon-alpha in a patient with Philadelphia chromosome-positive chronic myeloid leukemia.
    Verbeek W; König H; Boehm J; Kohl D; Lange C; Heuer T; Scheibenbogen C; Reis HE; Hochhaus A; Graeven U
    Acta Haematol; 2006; 115(1-2):109-12. PubMed ID: 16424660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of chronic myeloid leukemia using alpha-interferon and hydroxyurea. Study of 30 cases].
    Nese M; de Bellis R; Urtiarte R; Di Landro J
    Sangre (Barc); 1994 Jun; 39(3):183-6. PubMed ID: 7940047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-mediated complications during interferon alpha therapy in chronic myelogenous leukemia.
    Tóthová E; Kafková A; Stecová N; Fricová M; Guman T; Svorcová E
    Neoplasma; 2002; 49(2):91-4. PubMed ID: 12088112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate.
    Alimena G; Breccia M; Luciano L; Quarantelli F; Diverio D; Izzo B; De Angelis B; Mancini M; Latagliata R; Carmosino I; Nanni M; Picardi M; Rotoli B; Mandelli F; Pane F
    Leuk Res; 2008 Feb; 32(2):255-61. PubMed ID: 17692911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon.
    Breccia M; Diverio D; Pane F; Nanni M; Russo E; Biondo F; Frustaci A; Gentilini F; Alimena G
    Leuk Res; 2006 Dec; 30(12):1577-9. PubMed ID: 16630657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.